**ROLE SUMMARY** The Lung cancer portfolio is one of the fastest growing portfolios in Pfizer Oncology and includes the following brands: LORBRENA, BRAFTOVI/MEKTOVI Lung and XALKORI. Lung cancer is the most common cancer, and LORBRENA, our ALK+ inhibitor has been prescribed to over 12,000 patients since launching in the US in 2018. At ASCO 2024, […]
